DUBLIN, Dec. 21, 2017 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on December 20, 2017 seeking marketing approval for solriamfetol (JZP-110), an investigational medicine for...
from PR Newswire: //www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-submits-new-drug-application-for-solriamfetol-jzp-110-for-excessive-sleepiness-665662603.html
No comments:
Post a Comment